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Abstract
Purpose In addition to lowering hemoglobin A1C,
colesevelam has been shown to improve the atherogenic lipo-
protein profile of subjects with type 2 diabetes mellitus
(T2DM) when used in combination with metformin and/or
sulfonylureas. A recent study evaluated the effects of
colesevelam as antidiabetes monotherapy in adults with
T2DM who had inadequate glycemic control (hemoglobin
A1C ≥7.5 to ≤9.5 %) with diet and exercise alone; we report
here the effects on lipoprotein particle subclasses.
Methods Subjects were randomized to receive oral
colesevelam 3.75 g/day (n=176) or placebo (n=181) for
24 weeks. Changes in lipoprotein particle subclasses were
determined by nuclear magnetic resonance spectroscopy.
Results At Week 24 with last observation carried forward,
colesevelam produced a reduction in total low-density lipo-
protein (LDL) particle concentration (baseline: 1,611 nmol/L;
least-squares [LS] mean treatment difference: −143 nmol/L,
p<0.0001) versus placebo; reductions were also seen in large,
small, and very small LDL particle concentrations (all
p<0.05). There was also a reduction in total very low-
density lipoprotein (VLDL) and chylomicron particle concen-
tration (baseline: 88 nmol/L; LS mean treatment difference:
−1 nmol/L, p=0.82) that resulted from a lowering in small
VLDL particle concentration (baseline: 45 nmol/L; LS mean
treatment difference: −5 nmol/L, p=0.03). In addition, with
colesevelam there was an increase in total high-density lipo-
protein (HDL) particle concentration versus placebo (baseline:
31 μmol/L; LS mean treatment difference: +0.6 μmol/L,
p=0.20), due to increases in the large (baseline: 5 μmol/L;
LS mean treatment difference: +0.5 μmol/L, p=0.007) and
medium (baseline: 3 μmol/L; LS mean treatment difference:
+0.8 μmol/L, p=0.02) HDL subclasses.
Conclusions Colesevelam monotherapy in subjects with
T2DM resulted in generally favorable changes in certain
lipoprotein subclass profiles compared with placebo.
Keywords Colesevelam .Monotherapy . Lipoprotein
particles . Low-density lipoprotein . Nuclear magnetic
resonance . Type 2 diabetesmellitus
Introduction
Insulin resistance and type 2 diabetes mellitus (T2DM) are
associated with a variety of lipid and lipoprotein abnormali-
ties, including reduced high-density lipoprotein (HDL) cho-
lesterol levels, elevated triglyceride levels, and an altered
distribution of lipoprotein particles [1]. Patients with insulin
resistance also have alterations to the lipoprotein subclass
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profile that are not reflected by standard lipid panels [2, 3]. In
particular, very low-density lipoprotein (VLDL) particle con-
centration (VLDL-P) and low-density lipoprotein (LDL) par-
ticle concentration (LDL-P) are increased and HDL particle
concentration (HDL-P) is decreased in patients with insulin
resistance or T2DM compared with individuals who have
normal insulin sensitivity [2]. Among the lipoprotein sub-
classes, VLDL particle sizes are increased and LDL and
HDL particle sizes are decreased in patients with insulin
resistance or T2DM. These effects are seen despite normal
or near-normal levels of LDL cholesterol and total cholesterol
[3].
This altered distribution of lipoprotein particles (particular-
ly LDL particles) is relevant to cardiovascular disease (CVD)
risk [4]. LDL-P is predictive for coronary endothelial dysfunc-
tion and CVD risk [5, 6] and may be a better predictor than
LDL cholesterol, especially in patients with insulin resistance
or T2DM [4, 7–9]. In addition, HDL-P is inversely correlated
with carotid intima-media thickness and coronary heart dis-
ease risk [10–12]. Consequently, reducing total LDL-P
through changes in the distribution of lipoprotein particles in
patients with hypercholesterolemia via intervention with lipid-
lowering agents is a potentially good therapeutic strategy to
reduce CVD risk [13]. However, it should be noted that
although clinical data exist demonstrating the ability of some
cholesterol-lowering drugs to improve the LDL subclass dis-
tribution profile, the supporting data come from predominate-
ly smaller studies. Thus, the ability of these agents to reduce
vascular risk still needs to be demonstrated in large clinical
trials. For example, it is important to determine the clinical
benefit of drug regimens that reduce small LDL particle
fractions versus those that reduce all fractions simultaneously,
as well as to identify the subclass distribution profile produced
by each lipid-lowering agent, so that an agent may be chosen
to appropriately modify the lipid profile of the individual
patient [14]. In addition, determining which agents increase
HDL-P is also important, as HDL-P is inversely correlated
with carotid intima-media thickness and cardiovascular
events, and therefore administering an agent that increases
HDL-P may help to further reduce CVD risk [10–12, 15].
The bile acid sequestrant colesevelam has been shown to
improve glycemic and lipid parameters in subjects with
T2DM when added to metformin-, sulfonylurea-, or insulin-
based therapy [16–19]. In addition, treatment with
colesevelam in combination with metformin and/or sulfonyl-
ureas has been shown to result in a more beneficial lipoprotein
profile in subjects with T2DM [20, 21]. A recent study eval-
uated the effects of colesevelam as an antidiabetes monother-
apy in adults with T2DM who were inadequately controlled
by diet and exercise alone (ClinicalTrials.gov identifier:
NCT00789737) [22]. Here we report the effects of
colesevelam monotherapy on the concentrations and sizes of
various lipoprotein particle subclasses from this study.
Materials and Methods
Study Design
This was a 24-week, randomized, double-blind, placebo-
controlled, parallel-group study conducted at approximately
80 study centers in the United States. The study was conduct-
ed in compliance with independent ethics committee/
institutional review board regulations, good clinical practice
guidelines, and the principles of the Declaration of Helsinki.
Institutional review board approval was obtained before initi-
ation of the study, and all subjects provided written informed
consent.
Details of this study, including design, inclusion/exclusion
criteria, and statistical methods, have been described previ-
ously [22]. Briefly, the study enrolled subjects aged ≥18 years
with a diagnosis of T2DM (based on American Diabetes
Association diagnostic criteria) who were untreated at the time
of screening (i.e. treatment-naïve or not receiving
antihyperglycemic medication within ≥3 months prior to
screening). Subjects were required to have a hemoglobin
A1C (A1C) level ≥7.5 % and ≤9.5 % at screening, a fasting
plasma glucose (FPG) level ≤240 mg/dL at randomization,
and a fasting C-peptide level >0.5 ng/mL at screening. Sub-
jects were not randomized if they had persistent FPG levels
>240 mg/dL during the placebo lead-in period.
Following a 2-week single-blind placebo lead-in period,
subjects were randomized to receive oral colesevelam 3.75 g/
day (6×625 mg tablets) or placebo for 24 weeks. Subjects
taking concomitant medications must have been at stable
doses for ≥30 days prior to enrollment and not have been
anticipated to require adjustment during the study period. To
the extent possible, subjects were instructed to maintain the
same dosages of established lipid-lowering agents throughout
the double-blind treatment period to minimize confounding
the evaluation of the lipid-lowering effects of colesevelam
versus placebo.
Assessments
Scheduled clinic visits were at Weeks 0, 4, 8, 16, and 24 after
an overnight fast. Samples for chemistry, hematology, A1C,
and FPG were collected at screening and every visit from
baseline (Week 0) to the end of treatment (Week 24). The
primary efficacy variable was A1C level at Week 24. Secondary
efficacy variables included FPG, high-sensitivity C-reactive
protein, total cholesterol, LDL cholesterol, HDL cholesterol,
non-HDL cholesterol, triglyceride, apolipoprotein A-I (apoA-I),
and apoB levels. A standard meal tolerance test was conducted
at baseline and at Week 24 to evaluate the glucose excursion.
Fasting blood samples were obtained for the assessment of
lipid particle parameters at baseline and Week 24. Particle
parameters were determined by nuclear magnetic resonance
230 Cardiovasc Drugs Ther (2014) 28:229–236
(NMR) spectroscopy [23]. In this technique, distributions
and concentrations of individual lipid particle subclasses
are determined based on the fact that lipoprotein particles
within a specified diameter range emit a distinctive mag-
netic resonance signal with its signal intensity proportional
to lipid mass concentration [14, 24]. This analysis evalu-
ated changes in lipid particle parameters (mean lipoprotein
particle concentrations and sizes) from baseline to Week
24.
Statistics
The intention-to-treat (ITT) population was the primary pop-
ulation for analysis, defined as all randomized subjects who
received ≥1 dose of study medication and had an A1C or FPG
measurement at baseline and ≥1 post-baseline measurement
prior to taking any antihyperglycemic rescue medication. The
analysis compared changes from baseline between
colesevelam and placebo to rescue or Week 24 with last
observation carried forward (LOCF) using the ITT popula-
tion. Between-group differences were evaluated using an
analysis of covariance model, with treatment as a fixed effect
and baseline as a covariate; all statistical tests were 2-sided at a
5 % significance level. Because of the low number of subjects
on HMG-CoA reductase inhibitors (statins), the results were
not analyzed separately according to those subjects taking




A total of 357 subjects were randomized to receive
colesevelam (n=176) or placebo (n=181); the ITT population
comprised 344 subjects (175 and 169, respectively). Demo-
graphic and baseline characteristics of all randomized subjects
were generally similar between treatment groups, as summa-
rized in Table 1. The mean age was 52.2 years and a high
percentage of subjects were Hispanic/Latino (46.5 %). The
mean duration of T2DM was 4.1 years and the mean body
mass index was 31.9 kg/m2. Overall, 14.2 % of subjects in the
ITT population were taking statins and 2.9 % were taking
fibrates. Mean changes in weight from baseline to end of
study/early termination were similar for subjects in both the
Table 1 Demographic and base-





a There were no statistically
significant between-group
differences for any demographic
variable or baseline variable
Characteristica Colesevelam (n=176) Placebo (n=181)
Age (years), mean (SD) 52.6 (10.25) 51.8 (10.52)
Sex, n (%)
Male 94 (53.4) 89 (49.2)
Race, n (%)
Caucasian 122 (69.3) 131 (72.4)
Black 27 (15.3) 29 (16.0)
Asian 12 (6.8) 8 (4.4)
American Indian/Alaskan native 12 (6.8) 11 (6.1)
Native Hawaiian/Pacific Islander 1 (0.6) 0 (0.0)
Other 2 (1.1) 2 (1.1)
Ethnicity, n (%)
Hispanic/Latino 86 (48.9) 80 (44.2)
Not Hispanic/Latino 90 (51.1) 101 (55.8)
Body mass index (kg/m2), mean (SD) 32.0 (6.50) 31.8 (4.94)
Hemoglobin A1C (%), mean (SD) 8.25 (0.684) 8.18 (0.697)
Fasting plasma glucose, mg/dL, mean (SD) 172.5 (46.44) 168.0 (37.61)
Fasting insulin, μIU/mL, mean (SD) 17.7 (16.63) 17.9 (14.04)
Duration of type 2 diabetes (years), mean (SD) 4.3 (4.69) 3.9 (4.39)
Total cholesterol (mg/dL), mean (SD) 202.9 (39.69) 200.6 (40.37)
LDL cholesterol (mg/dL), mean (SD) 122.5 (33.80) 119.0 (33.17)
HDL cholesterol (mg/dL), median (range) 43.0 (23.0–84.5) 43.5 (24.0–100.0)
Non-HDL cholesterol (mg/dL), mean (SD) 159.4 (38.39) 155.8 (39.83)
Triglycerides (mg/dL), median (range) 162.3 (49.0–675.0) 169.0 (48.0–680.0)
Apolipoprotein A-I (mg/dL), mean (SD) 145.8 (21.62) 146.6 (23.99)
Apolipoprotein B (mg/dL), mean (SD) 114.0 (25.99) 113.7 (28.06)
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colesevelam and placebo groups (−0.58 and −0.70 kg,
respectively).
Efficacy
From baseline to Week 24, treatment with colesevelam, com-
pared with placebo, resulted in significant least-squares (LS)
mean reductions in A1C (treatment difference: −0.3 %;
p=0.01; primary efficacy variable), LDL cholesterol
(−13.6 mg/dL; p<0.0001), total cholesterol (−9.8 mg/dL;
p=0.0017), non-HDL cholesterol (−11.1 mg/dL; p=0.0004),
and apoB levels (−7.0mg/dL; p=0.0002). A significant median
increase in triglycerides (treatment difference: 16.5 mg/dL;
p<0.05) and LS mean increase in apoA-I levels (treatment
difference: 3.4 mg/dL; p<0.05) was also observed with
colesevelam compared with placebo [22]. The percent changes
in lipid parameters from baseline to Week 24 are shown in
Table 2. Colesevelam resulted in statistically significant mean
percent reductions in total cholesterol, LDL-C, non-HDL-C,
apoB, and apoA-I levels, and a statistically significant median
percent increase in triglycerides, compared with placebo.
Nuclear Magnetic Resonance Findings
Subjects who received colesevelam, compared with pla-
cebo, had significant reductions in total LDL-P (base-
line: 1,611 nmol/L; LS mean treatment difference:
−143 nmol/L; p<0.0001), as well as large (baseline:
339 nmol/L; −60 nmol/L; p=0.002), small (baseline:
1,203 nmol/L; −82 nmol/L; p<0.05), and very small
LDL-P (baseline: 963 nmol/L; −73 nmol/L; p=0.03; Table 3).
Although the subjects who received colesevelam had both
improvements in glycemic control and reductions in LDL-P,
post-hoc correlation analysis showed no significant correla-
tions between changes in LDL-P and changes in A1C or FPG.
Change in LDL particle size was not significantly different
between the treatment groups (Fig. 1).
Subjects in the colesevelam group, compared with the
placebo group, had a nonsignificant reduction in total VLDL
and chylomicron particle concentration (LS mean treatment
difference: −1 nmol/L; p=0.82) resulting from a significant
reduction in small VLDL-P (−5 nmol/L; p=0.03; Table 3). An
increase in VLDL particle size was also seen with
colesevelam (p=0.001; Fig. 1).
Treatment with colesevelam relative to placebo was also
associated with a nonsignificant increase in total HDL-P
(0.6 μmol/L; p=0.20) attributable to significant increases in
large (0.5 μmol/L; p=0.007) and medium (0.8 μmol/L;
p=0.02) HDL-P (Fig. 1). HDL particle size was also
increased relative to placebo in subjects treated with
colesevelam (p<0.0001; Fig. 1).
Subjects who received colesevelam, compared with place-
bo, also had statistically significant percent changes from
baseline in total LDL-P (LS mean percent treatment differ-
ence: −10 %; p<0.0001), small VLDL-P (−13 %; p<0.05),
and medium HDL-P (167 %; p=0.002). The percent changes
were not significantly different between colesevelam and
placebo for the other particle classes.
Safety
Overall, 16 (9.4 %) and 33 (18.9 %) subjects in the placebo
and colesevelam groups, respectively, had an adverse event
(AE) considered related to study medication. Hypoglycemia
occurred at a higher incidence in the colesevelam treatment
group compared with placebo (4.0 % vs. 0.6 %) and was
generally mild overall. The majority of AEs were mild or
moderate in severity. As reported in the primary study publi-
cation [22], a serious AE was reported by 4.0 % and 1.8 % of
subjects in the colesevelam and placebo groups, respectively,
Table 2 Percent change in lipid parameters
Parameter N Percent change from baseline
Treatment difference
LS mean LS mean p-value
Total cholesterol, mg/dL
Placebo 160 2 −5 <0.001
Colesevelam 164 −3
LDL-C, mg/dL
Placebo 160 1 −11 <0.0001
Colesevelam 162 −10
HDL-C, mg/dL
Placebo 160 −0.1 2 0.31
Colesevelam 164 2
Non-HDL-C, mg/dL
Placebo 160 3 −7 <0.001
Colesevelam 164 −4
Triglyceride, mg/dLa
Placebo 160 6 10 0.03
Colesevelam 164 15
apoA-I, mg/dL
Placebo 160 0.9 2 0.04
Colesevelam 164 3
apoB, mg/dL
Placebo 160 0.9 −6 <0.001
Colesevelam 164 −6
Reported changes are measured from baseline to Week 24 with last
observation carried forward (intent-to-treat population)
apoA-I apolipoprotein A-I, apo B apolipoprotein B, HDL-C high-density
lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, LS
least squares
a Parameter is not normally distributed. The median value is reported
rather than the mean value
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and none were considered by investigators to be related to
study medication. The most frequently reported AEs were
back pain (5.1 %) and headache (4.6 %) in the colesevelam
group and urinary tract infection (8.8 %) and nasopharyngitis
(5.3 %) in the placebo group. There were no clinically impor-
tant differences observed between the colesevelam and place-
bo groups in safety laboratory parameters.
Discussion
This study in adults with T2DM of relatively short duration
(mean 4.1 years overall) demonstrated generally favorable
changes to the lipoprotein particle profile among those who
received colesevelam as an antidiabetes monotherapy, com-
pared with those who received placebo. Significant effects
were seen on LDL particles (a reduction in total LDL-P
largely attributable to reductions in small and very small
LDL-P, as well as large LDL-P), VLDL particles (an increase
in VLDL particle size with an accompanying reduction in
small VLDL-P), and HDL particles (an increase in HDL
particle size with accompanying increases in large and medi-
um HDL-P).
It is increasingly recognized that the lipoprotein profile
affects CVD risk, although the influence of lipoprotein size
as an independent predictor of CVD risk is less clear than that
of lipoprotein concentration [5, 11, 25–27]. LDL-P is predic-
tive for coronary endothelial dysfunction and CVD risk [5, 6].
In one study, LDL-P was the strongest predictor of future
CVD events of the lipoprotein parameters determined by
NMR, with the risk for subsequent CVD events among sub-
jects in the highest quartile of LDL-P being >4-fold that of the
risk among subjects in the lowest quartile [5]. LDL-P
remained significant even after adjusting for other lipid pa-
rameters, suggesting that LDL-P provides additional risk data
beyond that provided by traditional lipoprotein parameters.
Increased HDL-P and large HDL have also been shown to be
associated with a reduction in CVD [6, 10, 25].
Importantly, LDL-P may be a better predictor of CVD than
LDL cholesterol [4, 7–9]. Many patients with increased car-
diometabolic risk have relatively normal LDL cholesterol
levels but have abnormal distributions of lipoprotein particles
[4, 9]. Thus, LDL cholesterol incompletely measures the risk
for coronary artery disease (CAD) [6, 8, 9, 28]. In particular,
since many patients with metabolic syndrome have a relative-
ly normal LDL cholesterol level but an elevated LDL-P,
traditional monitoring of LDL cholesterol may underestimate
CVD risk [28]. Our finding that colesevelam reduced LDL
cholesterol levels and LDL-P (primarily through reductions in
small and very small LDL-P) reflects a shift to a less athero-
genic profile. Small LDL particles have been shown in several
studies to be predictive of CVD events and CAD [11, 29, 30].
Table 3 Change in lipid particle concentrations
Parameter Baseline Endpoint Change from baseline
Treatment
difference
LS mean LS mean p-valuea
Total LDL-P, nmol/L
Placebo 1,563 1,591 24 −143 <0.0001
Colesevelam 1,611 1,487 −119
Large LDL-P, nmol/L
Placebo 325 328 2 −60 0.002
Colesevelam 339 278 −59
Medium small LDL-P, nmol/L
Placebo 236 240 3 −9 0.31
Colesevelam 240 234 −6
Small LDL-P, nmol/L
Placebo 1,169 1,195 22 −82 <0.05
Colesevelam 1,203 1,140 −60
Very small LDL-P, nmol/L
Placebo 933 955 19 −73 0.03
Colesevelam 963 906 −54
Total VLDL-P/chylomicron, nmol/L
Placebo 86 92 6 −0.8 0.82
Colesevelam 88 94 5
Large VLDL/chylomicron, nmol/L
Placebo 6 7 0.7 1 0.08
Colesevelam 6 8 2
Medium VLDL, nmol/L
Placebo 38 41 4 4 0.17
Colesevelam 38 45 7
Small VLDL, nmol/L
Placebo 42 44 2 −5 0.03
Colesevelam 45 41 −3
Total HDL-P, umol/L
Placebo 31 32 0.4 0.6 0.20
Colesevelam 31 32 1
Large HDL-P, umol/L
Placebo 5 5 −0.2 0.5 0.007
Colesevelam 5 5 4
Medium HDL-P, umol/L
Placebo 3 3 0.2 0.8 0.02
Colesevelam 3 4 1
Small HDL-P, umol/L
Placebo 24 24 0.3 −0.8 0.10
Colesevelam 24 23 −0.5
Reported changes are measured from baseline to Week 24 with last
observation carried forward (intent-to-treat population)
HDL-P high-density lipoprotein particle concentration, LDL-P low-den-
sity lipoprotein particle concentration, LS least squares, VLDL-P very
low-density lipoprotein particle concentration
a p-values are not adjusted for multiple comparisons
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These results are in line with previous studies showing that
colesevelam decreases LDL-P and increases LDL particle size
in subjects with hypercholesterolemia [31], prediabetes [32],
or T2DM [20, 21]. In the previous studies in subjects with
T2DM [20, 21], as in the current study, the reduction in LDL-
P was largely attributable to reductions in the smaller LDL
particle subclasses: small LDL-P, as well as very small LDL-P
(assessed in the current study). The reduction in very small
LDL-P with colesevelam is notable given that such an effect is
not seen with all other lipid-lowering agents, with some even
showing an increase in this parameter [33, 34].
Despite the increase in largeVLDL-P, colesevelam reduced
glucose levels, which suggests that the increase in large
VLDL-P does not result from worsened insulin resistance.
There was also a lack of correlation between reductions in
LDL-P and reductions in A1C or FPG. This may reflect the
current understanding of colesevelam’s independent
mechanisms of LDL cholesterol lowering (via deactiva-
tion of the farnesoid X receptor in the intestine) and
glucose lowering (via stimulation of TGR5 in the colon,
secretion of the incretin hormone glucagon-like peptide-
1, and reduced hepatic glucose production through sup-
pression of glycogenolysis) [35].
A strength of this study is that the observed lipid effects can
be directly attributed to colesevelam since only a small pro-
portion of subjects administered colesevelam was on
preexisting statin therapy. However, the small portion of sub-
jects on statin therapy also limits the ability to analyze cohorts
based on the use of a statin in combination with colesevelam
versus colesevelam therapy alone. Consequently, it would be
difficult to extrapolate the study results to determine the effect
of colesevelam in patients with T2DM and elevated LDL-
cholesterol levels who were already taking a statin. However,
it is noteworthy that a pooled analysis of data from three
pivotal studies in patients with T2DM showed that adding
colesevelam to concomitant statin therapy significantly re-
duced LDL cholesterol by an additional 16 % compared with
a 1% reduction in patients receiving placebo plus concomitant
statin therapy (p<0.0001) [36]. In addition, compared with
previous studies assessing the lipoprotein particle profile,
subjects in the present study were not taking other
antihyperglycemic medications such as metformin and/or sul-
fonylurea as they had in the previous studies [20, 21]. Thus,
the effect of colesevelam on the lipid profile described in the
present study would not have been influenced by prior or
concomitant exposure to other antidiabetes agents.
Conclusions
In subjects with T2DM, colesevelam as an antidiabetes mono-
therapy produced generally favorable changes in the lipopro-
tein particle profile compared with placebo.
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Fig. 1 Least-squares mean
change in lipid particle size, from
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